TERT Promoter Mutations Differently Correlate with the Clinical Outcome of MAPK Inhibitor-Treated Melanoma Patients

TERT Promoter Mutations Differently Correlate with the Clinical Outcome of MAPK Inhibitor-Treated Melanoma Patients

Resistance is a major challenge in the management of mitogen-activated protein kinase inhibitor (MAPKi)-treated metastatic melanoma. Tumor genetic alterations can cause MAPK pathway reactivation, leading to lack of response and poor outcome. Characterization of the mutational profile in patients wit...

Full description

Bibliographic Details
Main Authors: Paola Del Bianco, Camilla Stagni, Silvia Giunco, Alessio Fabozzi, Lisa Elefanti, Stefania Pellegrini, Antonella Vecchiato, Jacopo Pigozzo, Carolina Zamuner, Anita De Rossi, Arcangela De Nicolo, Chiara Menin
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:Cancers
Subjects:
melanoma
TERT promoter
MAPK pathway
MAPK inhibitors
Online Access:https://www.mdpi.com/2072-6694/12/4/946

Internet

https://www.mdpi.com/2072-6694/12/4/946

Similar Items